Lama Skieker: Severe Thrombocytopenia Demands Systematic Diagnosis Before Labeling ITP
Lama Skieker, Clinical Pathologist at Bader Alsama Barka, shared a post on LinkedIn:
“A recent hematology case reminded me how important it is not to label every case of severe thrombocytopenia as immune thrombocytopenia (ITP) too early.
A patient presented to the Emergency Department with:
- Fever for more than one week, Myalgia,Elevated CRP
- Severe thrombocytopenia (~33 × 10⁹/L)
Testing for dengue and malaria was negative.
The peripheral blood smear confirmed true thrombocytopenia with normal platelet morphology and distribution, and a repeat sample confirmed the CBC result.
Despite transfusion of multiple platelet units, there was no significant platelet count increment.
This raises an important diagnostic question:
Are we dealing with immune-mediated platelet destruction, ongoing platelet consumption, platelet transfusion refractoriness, or an underlying infectious or drug-related process?
Before diagnosing primary ITP, it is essential to maintain a broad differential diagnosis.
Conditions that should be considered include:
- Immune thrombocytopenia (ITP): A diagnosis of exclusion after secondary causes such as viral infections, autoimmune disease, medications, hepatitis, HIV, and H. pylori have been evaluated.
- Thrombotic thrombocytopenic purpura (TTP) and other thrombotic microangiopathies: Consider if thrombocytopenia is accompanied by hemolysis, schistocytes, elevated LDH, renal dysfunction, or neurological findings.
- Hemolytic uremic syndrome (HUS): Particularly when thrombocytopenia is associated with microangiopathic hemolytic anemia and acute kidney injury.
- HELLP syndrome: An essential consideration in pregnant or postpartum patients with hemolysis, elevated liver enzymes, and thrombocytopenia.
- Heparin-induced thrombocytopenia (HIT): Evaluate recent heparin exposure, timing of platelet decline, thrombosis, and the 4Ts score before laboratory testing.
- Drug-induced immune thrombocytopenia: Always perform a careful medication review. Antibiotics, heparin, quinine-containing products, antiepileptics, NSAIDs, and several other medications may cause abrupt severe thrombocytopenia.
A systematic evaluation may include serial CBCs, repeat peripheral smear, coagulation profile, fibrinogen, D-dimer, LDH, bilirubin, haptoglobin, reticulocyte count, direct antiglobulin test (DAT), renal and liver function tests, blood and urine cultures, viral screening, autoimmune testing, medication review, and ADAMTS13 testing when TTP is suspected.
Take-home message:
evere thrombocytopenia with poor platelet transfusion response should prompt a systematic search for immune destruction, platelet consumption, infection, thrombotic microangiopathy, and drug-related causes rather than relying on platelet transfusion alone.
Every low platelet count tells a story. Our role is to identify the underlying mechanism before assigning the diagnosis.”
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 00:54Mary Catherine Moffett: Advancing Advocacy Together – Highlights from the Sanofi Bleeding Disorders Summit
-
Oct 9, 2026, 00:46Paris Margaritis: Assays vs Outcomes – Connecting FVIII Expression to Bleeding Phenotype in Hemophilia A
-
Oct 9, 2026, 00:39Rodrigo Arreola Diaz: The Rise of Concizumab for Hemophilia A and B
-
Oct 8, 2026, 23:27Shayan Mohammadmoradi: Happy to Be Back at the Midwest Platelet Conference for Its 20th Meeting
-
Oct 8, 2026, 23:18Lorena Arranz: Honoured to Contribute to the 6th Global MPN Symposium
-
Oct 8, 2026, 23:06Denis Oduor: Serving Citizens and Saving Lives Through Blood Donation During National Customer Service Week 2026
-
Oct 8, 2026, 22:51Jan Hartmann: Speaking on Global Trends in Plasma Collection at the 50th Meeting of the Japanese Society of Blood Services
-
Oct 8, 2026, 22:49Akshat Jain: Proud to Announce the Publication of Advances in Sickle Cell Disease
-
Oct 8, 2026, 22:49Ed Shovelin: Extending the Platelet Aggregation Testing Window to 72 Hours